Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Non-Current Assets (2016 - 2025)

Heron Therapeutics' Non-Current Assets history spans 14 years, with the latest figure at $17.8 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 26.2% year-over-year to $17.8 million; the TTM value through Dec 2025 reached $81.4 million, down 25.06%, while the annual FY2025 figure was $17.8 million, 26.2% down from the prior year.
  • Non-Current Assets reached $17.8 million in Q4 2025 per HRTX's latest filing, down from $19.6 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $51.3 million in Q4 2021 to a low of $17.8 million in Q4 2025.
  • Average Non-Current Assets over 5 years is $34.8 million, with a median of $35.6 million recorded in 2023.
  • Peak YoY movement for Non-Current Assets: soared 32.95% in 2022, then decreased 28.46% in 2024.
  • A 5-year view of Non-Current Assets shows it stood at $51.3 million in 2021, then decreased by 11.25% to $45.5 million in 2022, then dropped by 25.89% to $33.7 million in 2023, then fell by 28.46% to $24.1 million in 2024, then dropped by 26.2% to $17.8 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Non-Current Assets are $17.8 million (Q4 2025), $19.6 million (Q3 2025), and $21.2 million (Q2 2025).